- Ongoing, recruitingPhase III and phase IV (Integrated)
MEMENTO-A Phase 3b/4 Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to assess the impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging (CMR)
This study is looking at a new medicine called mavacamten for adults with a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It aims to see if the medicine can reduce the thickness of the heart walls and the size of the heart's upper chambers.
For: Symptomatic Obstructive Hypertrophic CardiomyopathyHungary · Finland · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
BMS CV027-031, A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
This study is looking at a new medicine called Mavacamten for adults with a heart condition called non-obstructive hypertrophic cardiomyopathy. It aims to see if the medicine can make people feel better and improve their exercise ability over 48 weeks.
For: Non-obstructive Hypertrophic CardiomyopathyCzechia · Belgium · Norway - Recruiting
Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
This study looks at how a medicine called mavacamten works for adults with a heart condition called obstructive hypertrophic cardiomyopathy (oHCM). It aims to understand patients' and doctors' experiences with this treatment in the US.
For: Obstructive Hypertrophic Cardiomyopathy (oHCM)United Kingdom - Active not recruitingPHASE4
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
This study looks at how a new medicine, mavacamten, affects the heart's structure in adults with a specific heart condition called hypertrophic cardiomyopathy. We'll use special MRI scans to see these changes, aiming to better understand the treatment's impact.
For: Cardiomyopathy, HypertrophicUnited States · Argentina · Australia - Recruiting
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
This study looks at how people with a heart condition called obstructive hypertrophic cardiomyopathy (HCM) are treated in real life. It compares a new medicine called mavacamten with other treatments, focusing on how patients feel and how their condition progresses over time.
For: Obstructive Hypertrophic CardiomyopathyUnited States · Austria · France - Active not recruitingPHASE3
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
This study is looking into a new medicine called mavacamten for teenagers (12-17 years old) with a heart condition called hypertrophic cardiomyopathy (HCM). It aims to see how well it works, if it's safe, and how the body handles it, to help improve symptoms.
For: Cardiomyopathy, HypertrophicUnited States · Australia · Canada - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)
This study looks at the long-term safety of a medicine called mavacamten for adults with a heart condition called hypertrophic cardiomyopathy. It follows people who have already taken part in previous studies of this medicine.
For: Hypertrophic cardiomyopathySpain · Netherlands · Denmark